01315nas a2200133   4500000000100000008004100001260001200042100001000054700001400064700001400078245007100092520100400163022001401167       2024                            d  c05/20241 aShi V1 aPoondru S1 aRajpara A00aLeprosy-Insufficient Evidence for Monthly Multidrug Therapy-Reply.3 a<p><strong>In Reply</strong>&nbsp;We thank Adler et al for their insightful comments regarding our article<span style="font-size:13.3333px"> </span>and the treatment of lepromatous leprosy. As highlighted by these authors, the US National Hansen’s Disease Program (NHDP) has traditionally recommended treating multibacillary leprosy with daily rifampin, dapsone, and clofazimine for 24 months.</p>

<p>However, as the authors mention, there have been recent new recommendations for monthly, rather than daily, multidrug leprosy therapy. Some of these recommendations have originated from the NHDP itself, including at a 2023 NHDP webinar. The University of Missouri–Kansas City infectious disease clinic also received this guidance for monthly treatment from the NHDP. Specific considerations that went into the decision for monthly multidrug treatment with rifampin, moxifloxacin, and minocycline for the patient in our article&nbsp;were access to care and treatment adherence concerns.</p>
  a2168-6084